Open, Randomized, Phase II Study of Glivec in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Plus 10 Year Extension Study.
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2014
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Jul 2014 Protocol has been amended to change in design term, inclusion/exclusion criteria and in primary endpoints.
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 May 2013 Planned number of patients changed from 56 to 55 as reported by ClinicalTrials.gov.